The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

RIF1  -  replication timing regulatory factor 1

Homo sapiens

Synonyms: FLJ10599, FLJ12870, Rap1-interacting factor 1 homolog, Telomere-associated protein RIF1
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of RIF1

  • A single injection of 25 microg of pE9iNOS DNA in a lipid vector into the centre of a murine sarcoma (RIF1) induced iNOS protein expression by four-fold and increased nitrite concentration eight-fold [1].
  • Our results are consistent with PDT-induced oxygen depletion (reduced pO2) leading to an increase in relative hypoxia in RIF1 tumors [2].
  • In the present studies, tumor oxygenation was measured before, during and after meta-tetrahydroxyphenylchlorin (mTHPC)-mediated PDT of murine RIF1 tumors and human mesothelioma xenografts (H-MESO1) [2].
  • Samples of rhabdomyosarcoma and RIF-1 experimental tumours were maintained at 4 degrees C, spun at 3 kHz and measured in 28-min acquisitions at 11.7 and 14 T. Metabolite stability was evaluated using four sequential 28-min acquisitions [3].
  • Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors [4].

High impact information on RIF1


Associations of RIF1 with chemical compounds


Analytical, diagnostic and therapeutic context of RIF1


  1. Evaluation of a synthetic CArG promoter for nitric oxide synthase gene therapy of cancer. Worthington, J., Robson, T., Scott, S., Hirst, D. Gene Ther. (2005) [Pubmed]
  2. Oxygen depletion during and after mTHPC-mediated photodynamic therapy in RIF1 and H-MESO1 tumors. Schouwink, H., Oppelaar, H., Ruevekamp, M., van der Valk, M., Hart, G., Rijken, P., Baas, P., Stewart, F.A. Radiat. Res. (2003) [Pubmed]
  3. Evaluation of 31P high-resolution magic angle spinning of intact tissue samples. Payne, G.S., Troy, H., Vaidya, S.J., Griffiths, J.R., Leach, M.O., Chung, Y.L. NMR in biomedicine. (2006) [Pubmed]
  4. Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Yau, K., Price, P., Pillai, R.G., Aboagye, E. Eur. J. Nucl. Med. Mol. Imaging (2006) [Pubmed]
  5. Use of thymidine analogues to indicate vascular perfusion in tumours. Begg, A.C., Hofland, I., Van Der Pavert, I., Van Der Schueren, B., Haustermans, K. Br. J. Cancer (2000) [Pubmed]
WikiGenes - Universities